[Specificity of the management of metastatic renal cancer in the older patient].
Spécificité de la prise en charge du cancer du rein métastatique chez le patient âgé.
Cancer du rein
Elderly
Immunotherapies
Immunothérapies
Kidney cancer
Personne âgé
Targeted therapies
Thérapies ciblées
Journal
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
03
08
2019
accepted:
19
08
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
10
4
2020
Statut:
ppublish
Résumé
To define the necessary arrangements of medical treatment with anti-angiogenics, mTOR inhibitor or systemic immunotherapies in the management of metastatic renal cell carcinoma in elderly patients. Bibliographical search was performed from the Medline bibliographic database (NLM Pubmed tool) and Embase focused on: metastatic renal cell carcinoma, elderly, treatment. The selection criteria for the medical treatment of metastatic renal cell carcinoma in elderly patients are the IMDC score, necessarily complemented by performance status, the tolerability profile of treatments, more frequent drug interactions, treatment adherence, management capacity of side effects, and patient preference. Each of these criteria is detailed in critical ways. The efficacy and tolerability of medical treatments for metastatic renal cancer have not been reported as different depending on age. No dosage adjustment is recommended in principle. However, prevention and early treatment of side effects of treatment should be strengthened in elderly patients.
Identifiants
pubmed: 31771770
pii: S1166-7087(19)30474-9
doi: 10.1016/j.purol.2019.08.272
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
874-895Informations de copyright
Copyright © 2019 Elsevier Masson SAS. All rights reserved.